← Leaderboards
Christopher Gibson
Recursion Pharmaceuticals, Llc
$2,708,192
Attributed
$3,515,236
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2015–20$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$3,515,236 · 4
By mechanism
R44$3,073,259 · 2
R43$441,977 · 2
Top collaborators
- Anthony John Donato4 shared
Others in their field
Top investigators on “Drug Discovery”
- David Heimbrook · Leidos Biomedical Research, Inc.$369,513,553
- Leonard Freedman · Leidos Biomedical Research, Inc.$255,277,443
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Ralph Parchment · Leidos Biomedical Research, Inc.$137,717,670
- Daniel Ernest Ford · Johns Hopkins University$137,014,543
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,294,869
Research focus
Drug DiscoveryCellsPharmacologic SubstanceSmall Business Innovation Research GrantCell TypePharmaceutical PreparationsScreeningSuccessImageImage AnalysisBasePhenotypeAffectPublic Health RelevanceAmericanMachine LearningDisease ModelClinical TrialsFunctional DisorderFluorescence ImagingPharmacotherapyCostComplexAlgorithms
Grant awards (8)
Novel Methodology for Identification of Senolytics that Reduce Age-related Disease and Dysfunction$447,905
R44 · FY2020 · AG · contact PI
Novel Methodology for Identification of Senolytics that Reduce Age-related Disease and Dysfunction$434,004
R44 · FY2019 · AG · contact PI
Novel Methodology for Identification of Senolytics that Reduce Age-related Disease and Dysfunction$509,173
R44 · FY2018 · AG · contact PI
Expansion of an efficient drug repurposing platform for rare genetic diseases.$650,041
R44 · FY2016 · TR · contact PI
Novel Methodology for Identification of Senolytics that Reduce Age-related Disease and Dysfunction$223,006
R44 · FY2016 · AG · contact PI
Expansion of an efficient drug repurposing platform for rare genetic diseases.$809,130
R44 · FY2015 · TR · contact PI
Application of an efficient drug repurposing platform to identify treatments for Cornelia De Lange Syndrome$224,625
R43 · FY2015 · HD · contact PI
HLS13-04 High-Content High-Throughput Screen for Diamond Blackfan Anemia Treatments$217,352
R43 · FY2015 · HL · contact PI